Recently, in-frame internal tandem duplications have been reported within the regions coding for the juxtamembrane through the first tyrosine kinase domain of the Flt3 gene. These duplications have been reported to lead to autophosphorylation of the receptor. In this study we investigated the effect of such mutations in the Flt3 gene on the in vitro proliferation of human acute myeloid leukemia cells. The mutations were detected in 10 out of 59 AML bone marrow samples analyzed and were not restricted to a specific FAB class or cytogenetic aberration. PCR analysis of those samples showed all mutations to be present in exon 11 of the gene. Whilst samples without a mutation of the Flt3 gene showed an increased cell production in response to either IL-3 and G-CSF or IL-6, SCF, TPO and Flt3L in long-term stroma supported cultures, mutant samples failed to do so. As we could not find a relationship between the absence of a response and either FAB class or cytogenetic aberrations, we interpret these results as an indication that the internal tandem duplications in the Flt3 gene are the prime cause of this unresponsiveness. Although our study does not explain the mechanism by which these mutations cause this unresponsiveness it does suggest that AML cells need a wild-type Flt3 for optimal in vitro proliferation.
Introduction
In normal hematopoiesis proliferation and differentiation is regulated by highly specific growth factor/growth factor receptor interactions. 1, 2 The fms-like tyrosine kinase 3 (Flt3), also known as stem cell tyrosine kinase-1 (STK1) or fetal liver tyrosine kinase-2 (FLK-2), [3] [4] [5] belongs to the group of receptor tyrosine kinases (RTKs) which also includes the receptors c-kit (the receptor for Kit-ligand or stem cell factor) and c-fms (the receptor for CSF-1). The RTKs have similar structural characteristics such as the presence of five Ig-like domains in their extracellular region. Signals generated by ligand-induced dimerisation of these receptors involve tyrosine phosphorylation of certain regions of the receptor and activation of cellular tyrosine kinases.
Whilst a large proportion of acute myeloid leukemias (AML) has been found to express c-kit and c-fms [6] [7] [8] and these are absent on blast cells of acute lymphoid leukemia, the potential role of this class III receptor superfamily is still unclear. Flt3 ligand (Flt3L) and Flt3 are both expressed on B-ALL and AML cells [9] [10] [11] [12] as wells as on normal progenitor cells. [13] [14] [15] Recently, internal tandem duplications (ITDs) were reported in the part of the Flt3 gene coding for the juxtamembrane (JM) through first tyrosine kinase (TK-1) domains of the protein.
Flt3/ITDs appeared to be present in 17-20% of AML patients 16, 17 as well as in leukemic transformation of myelodysplasia, 18 including 20% of patients with acute promyelocytic leukemia (APL). 19 However, these types of mutations have not been found in chronic myeloid leukemia (CML) or in CML blast crisis, 20 nor have they been reported in cells of normal individuals.
Kiyoi et al 21 have shown that elongation of the JM domain causes ligand-independent dimerisation of the mutant receptor, thus resulting in a constitutive activation. This effect was seen in both mutant/mutant and in mutant/wild-type dimers of the receptor. Immunoprecipitation studies of those mutant receptors showed evidence for a conformational change in the C-terminal region of the mutant receptor.
In the present study we investigated whether Flt3/ITDs would affect the proliferative capacity of leukemic cells in stroma-supported cultures. In addition, we also investigated whether a possible effect could be abrogated or enhanced by the addition of cytokines including IL-3 and G-CSF or IL-6, SCF, TPO and Flt3L.
We found that the presence of the mutation in 10 of 30 AML samples investigated correlated with a significant reduction in the ability to generate non-adherent cells during the entire culture period. This effect was most profound during weeks 2 and 3 of the culture period when most active proliferation was observed, while it was not affected by the cytokine combinations tested. We also found that both the mutation and its effect in the cultures were not correlated to either a specific FAB classification or cytogenetic background of the sample.
Materials and methods

Patient samples
Bone marrow cells were obtained after informed consent of patients with AML. Cases were classified according to the French-American-British committee (FAB). 22 Mononuclear cells were isolated by Ficoll separation followed by T cell depletion, typically resulting in a population containing over 95% blasts. After isolation cells were subjected to controlled freezing and stored in liquid nitrogen. Before use cells were thawed by stepwise dilution in Iscove's modified Dulbecco's medium (IMDM; Gibco, Breda, The Netherlands) containing 1% BSA. After thawing viability varied between 70 and 90% as assessed by dye exclusion.
Determination of Flt3 mutants
All AML samples were analyzed for mutations in exons 11 and/or 12 of the Flt3 gene by using a modified PCR procedure as described elsewhere 16 using the following primer sets: 11F (5′CAATTTAGGTATGAAAGCC-3′), 11R (5′-CAAACTCT-AAATTTTCTCT-3′) covering the complete exon 11 and 12F (5′-TGTCTTTGCAGGGAAGGTTAC-3′) and 12R (5′-GTACCTTTCAGCATTTTGAC-3′) covering exon 12 of the gene. These exons 11 and 12 allowed us to cover the whole JM and the first part of the TK-1 domain where most of the reported mutations are located. Genomic DNA was prepared using a standard procedure. 23 Briefly, DNA from around 10 4 cells was amplified in a total of 50 l reaction mixture, containing 1 × PCR buffer, 10 pM of each primer, 10 mM dNTPs and 0.5 U Taq polymerase (Supertaq; SpheroQ, Leiden, The Netherlands). Preheating of the samples at 95°C was followed by amplification for 35 cycles consisting of: 1 min at 43°C, 1 min at 72°C, 1 min at 95°C. Following these cycles a final extension at 72°C was performed for 10 min. PCR products were stained with SYBR green I (Molecular Probes, Leiden, The Netherlands) and resolved on 3% agarose gel.
As a confirmation samples positive for a flt3-mutation were reanalyzed in a second PCR using the primers 11F and 12R.
Sequencing of patient samples with a mutated Flt3 gene
IF both PCR reactions using the 11F/11R and 11F/12R combinations resulted in an abnormal PCR product, this was purified from the gel using a JETsorb kit (Genomed, Bad Oeyenhausen, Germany). This purified PCR product was subjected to a second PCR using fluorescent ddNTPs after which sequencing was carried out using an automated DNA sequencing system (ABI PRISM 310 genetic analyzer; Perkin Elmer Applied Biosystems, Foster City, CA, USA).
Long-term culture of AML cells
To assess the optimal conditions for long-term in vitro growth of the AML cells, we cultured the samples under the following conditions: (1) serum-free Stem Cell Growth Medium (SCGM; Biowhittaker, Alkmaar, The Netherlands) without stromal support; (2) SCGM with support of a stromal layer formed by the murine FBMD-1 cell line; 24 and (3) LTC medium consisting of IMDM, supplemented with 10% heat inactivated fetal calf serum (Summit Biotechnology, Fort Collins, CO, USA), 5% horse serum (Gibco), ␤-mercaptoethanol (5 × 10 −5 mol/l) and hydrocortisone-21-hemisuccinate (10 −6 mol/l; Sigma, St Louis, MO, USA) in the presence of a stromal layer. All of the above media were supplemented with penicillin (100 U/ml) and streptomycin (100 g/ml).
rhIl-3 (8 ng/ml), rhG-CSF (20 ng/ml) and rhIL-6 (100 ng/ml) were a generous gift of the Genetics Institute, Cambridge, MA, USA; rhSCF (50 ng/ml) and rhFlt3L (50 ng/ml) were a gift of Amgen, Thousand Oaks, CA, USA; and rhTPO (10 ng/ml) was a gift of Genentech. All cultures were performed in six-well cluster plates (Costar, Cambridge, MA, USA) at 37°C and 10% CO 2 in a humidified atmosphere. Volumes were standardized at 2 ml/well. Weekly, half of the medium was replaced and non-adherent nucleated cells were counted.
Detection of AML cells in culture
If the number of cultured cells produced allowed us, we determined their leukemic or normal hematopoietic background. This was done by May-Grunwald-Giemsa staining of cytospin preparations taken from the cultures. The lack of terminal differentiation and their strong resemblance to the original cell inoculum strongly suggested a leukemic origin.
Statistical analysis
Statistical analysis of the data was performed using the SPSS software package (SPSS, Chicago IL, USA). Significance of differences was determined by the non-parametrical MannWhitney U test. Values were considered significant if P values were below 0.05.
Results
Screening for the Flt3 mutation
A total of 59 bone marrow samples from patients with AML were screened for the presence of a Flt3 mutation. A total of 10 patients (17%) were found to be positive. All mutations found were in the exon 11 region of the gene whilst none were found in exon 12 (data not shown). All patients, except for patient 2 who had a homozygous mutation, showed a heterozygous mutation with both normal and mutated alleles detectable by PCR. The mutation was randomly distributed over the FAB classes and did not show a correlation with any known cytogenetic aberration.
As we were not aware of any reports on the presence of these types of mutations in the normal population we also checked 46 healthy volunteers. No mutations were found in these samples, thus reducing the possibility that these mutations reflect gene polymorphisms.
In this study the 10 AML patients with the mutation and 20 AML patients without such a mutation were more extensively studied. Patient details are shown in Table 1 .
The sequence analysis of the Flt3 mutant samples (Table 2 ) shows tandem duplications varying in length from 10 to 26 amino acids (30-78 bp). All mutations were restricted to the JM domain of the receptor. Four out of nine mutant samples show the same location for the start of the mutation whilst all others differ in their starting position. Patient No. 7 starts with a valine to leucine mutation caused by a G to C point mutation in the DNA.
All ITDs have the duplication of the putative SH2 binding motif YFYV as a common factor. Patients 2, 3, 6 and 10 also have a duplication of a second putative SH2 binding motif YEYD. The involvement of these motifs in the binding of SH2-containing signalling molecules by Flt3, however, remains to be elucidated.
Selection of the optimal culture conditions
To determine the optimal conditions for long-term culture the cells were grown in serum-free medium, with or without support of an adherent FBMD-1 stromal layer or in LTC medium (including 10% FCS and 5% HS) on a stromal layer. As shown in Figure 1 , after 3 weeks of culture, the stroma-supported cultures produced more cells than did the stroma-free cultures. This suggests a supporting role for stroma in maintaining longterm cultures of AML cells. In contrast to the cultures with stromal support, in stroma-free cultures cell production ceased between weeks 4 and 5 of culture. Stroma-supported cultures maintained production until the end of the 8-week observation period (data not shown). As the most optimal growth 
Figure 1
Effect of culture condition on the cumulative non-adherent nucleated cell production during 3 weeks of culture. All cultures were initiated with 10 5 nucleated cells/well. Cells were either cultured in: SCGM without support of a stromal layer and without serum ( ); SCGM with support of a stromal layer but without serum (`) or in IMDM with support of a stromal layer and serum (). Values represent mean ± s.e.m., N depicts the number of AML samples tested.
was observed in serum-containing stroma-supported cultures we performed all subsequent studies under these conditions.
Effect of the Flt3 mutation on the production of nonadherent cells
At week 1 of culture only a few samples showed a non-adherent (NA) nucleated cell production above the input value of 1 × 10 5 cells/well (Table 3) . With increasing culture time the various samples showed an increased variability in cumulative NA cell production. This is most clear in IL-3 and G-CSF containing cultures at week 8 where the lowest cumulative NA cell production (patient 3) was equal to the input value whilst the highest (patient 11) was 3.9 × 10 11 cells/well. In the absence of exogenous cytokines we observed a distinct group of samples with a significant (0.030 Ͼ P Ͼ 0.001) higher cumulative NA cell production. This group was comprised of patients 9 to 14 who all had a trisomy of chromosome 8 as a common aberration. At weeks 3 and 8 the cumulative NA cell production by the Flt3 mutant samples was significantly reduced in the groups without addition of growth factors and in those containing IL-3 and G-CSF (0.05 Ͼ P Ͼ 0.001). This reduction was also observed in the groups cultured with IL-6, SCF, TPO and Flt3L, although only significantly at week 3.
The weekly NA cell expansion, which is defined as the fold increase between two weekly counts (Figure 2) , enables a better understanding of the kinetics of the cell production. Expansion is maximal at weeks 2 and 3, irrespective of the growth factors used. At this time point the expansion in the nonmutant population is significantly higher than in the mutant population (0.05 Ͼ P Ͼ 0.02) when cultured either with the addition of IL-3 and G-CSF or without cytokine addition. No significant differences were found in the IL-6, SCF, TPO and ). −, time point not reached due to loss of culture (infection or detachment of the stromal layer).
Flt3L stimulated groups at week 3 but at week 2 the mutant population showed less expansion than the non-mutant population (P = 0.03). The analysis was repeated excluding the trisomy 8 samples as these were observed to grow more vigorously than the other samples (see Table 3 ). Although this exclusion reduced the significance (0.05 Ͼ P Ͼ 0.04, data not shown) the differences between non-mutant and mutant groups remained.
A selection of the samples according to their FAB classification ( Figure 3 ) allowed a further analysis of the responses to cytokine addition between the mutant and non-mutant groups. Although the effect of cytokine addition was visible throughout all FAB classes we also noted different cytokine responses between samples of specific FAB classes. In cultures that included IL-3 and G-CSF we observed a large expansion of the non-mutant samples in the M1, M2 and M5 groups. Remarkably, the Flt3 mutants within these groups did not respond. In the 2 week cultures that contained Il-6, SCF, TPO and Flt3L a clear response of the non-mutant samples was seen in FAB classes M0, M1, M2 and M4. The mutant samples showed no significant response to the addition of cytokines in any of the FAB classes.
As the subdivision of AML into FAB classes is mainly based on morphological and cytological criteria, we also classified Effect of Flt3 exon 11 mutation on the weekly expansion of the total AML population tested. The expansion factor is defined as the fold increased between two consecutive weekly counts. The horizontal black lines represent the median weekly expansion factors, shaded bars represent the interquartile range, whilst the error bars indicate extreme cases, eventual outlayers are marked by an asterisk. Dark shaded bars represent non-mutant samples, light shaded bars the mutant samples.
the samples according to their cytogenetic aberrations. As is apparent from Table 1 , most cytogenetic aberrations are present in at a low frequency. To allow for analysis, we tentatively defined groups that contain multiple aberrations, ie: (A) samples without any known aberrations; (B) samples exclusively containing one or more deletions; (C) samples exclusively containing additions; (D) translocations; (E) samples containing combinations of additions and deletions and (F) samples containing additions and translocations. Most samples were present in the groups with either no or a single type of aberration.
At week 2 of culture, proliferative responses to cytokine cytogenetic aberrations, the response to cytokines increased when compared to week 2. Again, no significant responses of the mutant groups were seen with the exception of cytogenetics group C when cultured in the presence of IL-6, SCF, TPO and Flt3L and in group D where the mutant samples showed a higher median expansion compared to the non-mutant samples at this time point.
Discussion
To our knowledge this is the first report suggesting a proliferative defect of AML cells carrying internal tandem duplications in exon 11 of the Flt3 gene. While non-mutant samples showed increased NA cell production in response to cytokine addition especially in weeks 2 and 3 of stroma-supported cul-tures, Flt3 mutant cells failed to do so. Other receptor mutations have been reported to have severe effects on proliferation or differentiation as well. As an example, specific truncations of the cytoplasmic domain of the human G-CSF receptor gene cause almost complete abrogation of granulocytic differentiation and are associated with a propensity of affected individuals towards myelodysplasia and leukemia. 25, 26 In our study we have attempted to see whether the observed low proliferative ability and unresponsiveness of Flt3 mutant samples to exogenous cytokines is related to either FAB class or cytogenetic aberrations. As we did not observe such a relationship, we interpret this as an indication that the Flt3 gene ITDs are the prime cause of the defective proliferative response rather than another defect in a specific AML subclass. We realise that all M3 and most M2 samples are included in the cytogenetic translocation group and that alternative classifications may, or may not, reveal a possible linkage of Flt3 gene ITDs with an AML subtype.
It is surprising that the cells carrying the Flt3/ITDs, in addition to Flt3L, showed unresponsiveness to a series of cytokines, including IL-3, IL-6, G-CSF, SCF and TPO. Our initial experiments indicated that AML cells could only be propagated ex vivo for a short time in serum-containing medium complemented with these cytokines, while stromal support was required for long-term cell production. Although stromal cells elaborate low concentrations of some of the cytokines employed in our study (ie IL-6, SCF and Flt3L), the stromal support presumably contributes to a different presentation of these growth factors (eg glycosaminoglycans), or the elaboration of alternative cytokines, inhibitors and/or expression cell-adhesion molecules.
Our study does not explain the mechanism by which ITDs in the Flt3 receptor gene cause a defect in the proliferative response of mutant AML cells. It seems, however, plausible to conclude that these mutations do not only affect the response to the Flt3L, but in addition that to other cytokines. This effect of the Flt3/ITDs is unlikely to be caused by a defect in a common intracellular signalling cascade but may rather be the result of either a disturbed synergy between Flt3 and other cytokines, or a disturbance in the sequence of cytokine signals which should lead to proliferation. As far as the limited number of analyses permit us to speculate, Flt3 mutant samples grow less well on a stromal layer in the absence of exogenous cytokines than do non-mutant samples (Figure 3a and 4a) , an observation suggesting that AML cells need a wild-type Flt3 receptor for optimal proliferation. Alternatively, if the Flt3 mutant samples contained relatively less AML progenitor cells than do normal samples, this may lead to reduced cell production and therefore an apparently diminished cytokine response. This alternative could be substantiated by assessing the actual number of AML stem and progenitor cells present in the starting population by leukemic CAFC and LTC assays 27, 28 which will be included in a subsequent study.
Another interesting observation was that AML samples with trisomy of chromosome 8 showed a much higher proliferative activity than did other AML samples, irrespective of the presence of a Flt3 gene ITD. A possible explanation for this observation is the over-expression of c-myc located on chromosome 8q24. Over-expression of c-myc has been described for immortalized tumor cell lines, while c-myc down-regulation in these cells often leads to differentiation. [29] [30] [31] [32] This observation suggests that selection of a small AML subset may strongly bias the results obtained.
The presently described functional defects in AML cells caused by Flt3 gene ITDs may contribute to our understanding of how a single cytokine receptor gene defect may influence the response to other cytokines and the potential role this might have in the development and progression of leukemia.
